Table 1. TP15-Fc binding to human lymphoma and leukemia cell lines.
| Cell line | Binding | RFI ± SD | |
|---|---|---|---|
| B cell derived | |||
| INA-6 | plasma cell leukemia | ++ | 15.2 ± 5.9 |
| JK-6L | multiple myeloma | + | 5.9 ± 0.2 |
| L363 | plasma cell leukemia | ++ | 9.8 ± 2.6 |
| MM1.S | multiple myeloma | + | 2.7 ± 1.7 |
| RPMI-8226 | multiple myeloma | +++ | 46.2 ± 0.8 |
| U266 | multiple myeloma | ++ | 25.8 ± 9.8 |
| ARH-77 | B-lymphoblastoid cells (EBV+) | + | 7.9 ± 2.2 |
| SEM | B cell precursor leukemia | - | 1.0 ± 0.1 |
| Daudi | Burkitt's lymphoma | ++ | 10.2 ± 2.1 |
| Raji | Burkitt's lymphoma | ++ | 17.2 ± 7.2 |
| Ramos | Burkitt's lymphoma | + | 6.0 ± 1.9 |
| T cell derived | |||
| CEM | T-ALL | - | 1.0 ± 0.2 |
| Jurkat | T-ALL | - | 1.0 ± 0.1 |
| Non-lymphoid | |||
| HEL | erythroleukemia | - | 1.2 ± 0.2 |
| KG-1a | immature AML | - | 1.5 ± 0.6 |
| HL60 | AML | - | 1.0 ± 0.2 |
| K562 | CML | (+) | 2.2 ± 0.5 |
RFI values calculated for binding of 10 μg/ml TP15-Fc relative to 4D5-Fc on 500.000 cells/sample. SD, standard deviation; EBV, Epstein-Barr virus; T-ALL, T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; +++ RFI > 30, ++ RFI > 10, + RFI > 2.5, - RFI < 2.